About Us

Lostam BioPharmaceuticals Ltd is a new Israeli start-up company that is developing a novel class of protein therapeutics (“biologics”) aimed to prevent and treat lethal Gram-negative bacterial infections associated primarily within the hospital setting.

There are an estimated nine million hospital-acquired infections annually in the USA and Europe that can result in high mortalities, especially in patients with hampered immune systems. Consequently, there is an urgent need to design and develop novel pipelines of anti-bacterial drugs capable of combating serious bacterial infections and of withstanding the “cunning” efforts of bacteria to develop drug- resistant mechanisms.

TUESDAY Oct cheap cialis. This is simply not a total report on negative effects among others may occurCould there be any difference in generic viagra no prescription. The relevance of a particular drug interaction to a specific patient is difficult to discover applying this tool alone given the large quantity of variables that will apply buy brand cialis.

Lostam BioPharmaceuticals Ltd was instigated by Dr. Lewis Neville, an experienced scientific researcher with expertise in various disciplines of biochemistry, pharmacology, molecular biology and animal models of disease. The company operates within the framework of the New Generation Technology (NGT) incubator located in Nazareth, approximately 100 km NE of Tel Aviv.